辽宁春光制药装备股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字|2024|001101119 号 大华会计师事务所(特殊普通合伙) DaHua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 报告编码:京24 辽宁春光制药装备股份有限公司 控股股东及其他关联方资金占用情况的专项说明 (截止 2023 年 12 月 31 日) 录 页 次 控股股东及其他关联方资金占用情况的专项 1-2 l 说明 II 辽宁春光制药装备股份有限公司 2023 年度非 1 经营性资金占用及其他关联资金往来情况汇 总表 86 (10) 5835 0011 传真: 86 (10) 583 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2024] 001101119 号 辽宁春光制药装备股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了辽宁春 光制药装备股份有限公司(以下简 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-021 辽宁春光制药装备股份有限公司 2023 年度内部控制自我评价报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《企业内部控制基本规范》《企业内部控制应用指引》的规定和其他内 部控制监管要求（以下简称企业内部控制规范体系），结合辽宁春光制药装备股 份有限公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，我们对公司截止 2023 年 12 月 31 日（内部控制评价报告 基准日）的内部控制有效性进行了评价： 一、重要声明 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷。董事会认为，公司已按照企业内部控制 规范体系和相关规定的要求在所有重大方面保持了有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷认定情况，于内部控制评价报告基准 日，公司未发现非财务报告内部控制重大缺陷。 公司已经建立起的内部控制体系在完整性、合规性、有效性等 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-014 辽宁春光制药装备股份有限公司 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的召集、召开符合《公司法》《公司章程》《监事会议事规则》的相 关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 3.回避表决情况 本议案不涉及关联交易，无需回避表决。 本议案尚需提交股东大会审议。 （二）审议通过《关于 2023 年年度报告及摘要的议案》 1.议案内容： 二、议案审议情况 （一）审议通过《关于 2023 年度监事会工作报告的议案》 1.议案内容： 公司监事会对 2023 年度工作运营情况、监事会工作情况进行了总结，形成 了 2023 年度监事会工作报告。 1.会议召开时间：2024 年 4 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 4 月 10 日 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-023 辽宁春光制药装备股份有限公司 （一）审阅公司财务报告并发表意见 报告期内，董事会审计委员会审议了公司各期财务报告，与公司管理层进行 了沟通，认为公司财务报告真实、准确、完整地反映了公司的经营成果及财务状 况，不存在虚假记载、误导性陈述或者重大遗漏，公司按照财政部、中国证监会 的有关规定，并根据公司实际情况本着谨慎的原则，选择和运用恰当的会计政策， 符合相关法规及《公司章程》的规定。 董事会审计委员会 2023 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 辽宁春光制药装备股份有限公司（以下简称"公司"）第三届董事会审计委 员会根据《公司法》《证券法》《上市公司独立董事管理办法》《北京证券交易所 股票上市规则（试行）》《公司章程》及《审计委员会议事规则》等相关法律法规 及公司制度的规定和要求，在 2023 年度认真履职。现将本年度履职情况汇报如 下： 一、基本情况 公司第三届董事会审计委员会由 3 名董事组成，分别 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-020 辽宁春光制药装备股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、权益分派预案情况 根据公司 2024 年 4 月 25 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 63,772,960.72 元，母公司未分配利润为 65,119,995.20 元。 公司本次权益分派预案如下：公司目前总股本为 68,500,000 股，以未分配利 润向全体股东每 10 股派发现金红利 1.00 元（含税）。本次权益分派共预计派发 现金红利 6,850,000.00 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登记结算有限责任公司北京分公司核算的结果为准。 二、审议及表决情况 （一）董事 ...

Financial Performance - Revenue for Q1 2024 was CNY 10,747,829.83, a significant decrease of 78.94% from CNY 51,045,814.36 in Q1 2023[12] - Net profit attributable to shareholders was a loss of CNY 3,342,147.31, down 143.49% from a profit of CNY 7,684,095.67 in the same period last year[12] - Operating profit for the same period was -4.04 million yuan, down 145.53% year-on-year, attributed to changes in market demand leading to decreased product revenue[15] - The net profit for the first quarter of 2024 was -3.50 million yuan, a decrease of 145.57% year-on-year, primarily due to a decline in revenue and gross margin[15] - The company's total comprehensive income for Q1 2024 was -¥4,077,480.89, compared to ¥7,982,611.80 in Q1 2023, highlighting a drastic shift in overall financial performance[52] Cash Flow - Operating cash flow for the quarter was a negative CNY 11,430,013.86, representing a decline of 305.55% compared to a negative CNY 2,818,387.26 in Q1 2023[12] - The net cash flow from operating activities was -12,258,376.66, compared to -2,433,742.72 in the previous year, indicating a significant decline[56] - Cash inflow from financing activities amounted to 12,589,419.41, while cash outflow was 568,649.24, resulting in a net cash flow of 12,020,770.17, compared to -1,620,487.88 previously[56] - The company reported a significant decrease in cash and cash equivalents, with a net decrease of 2,604,906.49 compared to -51,893,336.39 last year[56] Assets and Liabilities - Total assets increased by 3.66% to CNY 474,853,107.79 as of March 31, 2024, compared to CNY 458,091,452.82 at the end of 2023[12] - Total liabilities increased to CNY 195,129,520.70 from CNY 174,968,345.64, reflecting a rise of approximately 11.5%[45] - Current assets increased to CNY 290,555,082.54 as of March 31, 2024, up from CNY 273,910,270.25 on December 31, 2023, representing a growth of approximately 6.4%[43] - The company's total assets reached CNY 474,853,107.79, up from CNY 458,091,452.82, indicating a growth of about 3.5%[45] Shareholder Information - The total number of ordinary shares was 68.5 million, with 37.80% being unrestricted shares and 62.20% being restricted shares[19] - Major shareholders include Bi Chunguang with 26.72% and Bianjing with 19.85% of the shares[20] - There were no pledged or judicially frozen shares among the major shareholders[22] Research and Development - Research and development expenses increased by 46.57% to CNY 1,999,529.25, reflecting the company's commitment to enhancing R&D efforts[14] - Research and development expenses for Q1 2024 were CNY 1,999,529.25, compared to CNY 1,364,229.54 in Q1 2023, representing an increase of approximately 46.5%[49] Debt and Financing - The company's debt-to-asset ratio rose to 41.09% from 38.20% year-over-year, indicating increased leverage[12] - Short-term borrowings rose by 44.38% to CNY 40,955,897.22, driven by the need for working capital[14] - The company maintained its long-term borrowings at CNY 26,400,000.00, unchanged from the previous year[48] Other Financial Metrics - The weighted average return on equity dropped to -1.19% from 7.61% in the previous year, indicating a decline in profitability[12] - The company reported a credit impairment loss of CNY -417,522.35 in Q1 2024, worsening from CNY -333,763.53 in Q1 2023[50] - Total operating costs for Q1 2024 amounted to CNY 17,378,642.04, compared to CNY 42,403,116.82 in Q1 2023, indicating a decrease of about 58.9%[49]

证券代码：838810 证券简称：春光药装 公告编号：2024-015 辽宁春光制药装备股份有限公司 2023 年年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 我作为辽宁春光制药装备股份有限公司（以下简称"公司"）的独立董事，2023 年度，严格按照《公司法》《证券法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有关法律、法 规及《公司章程》《独立董事工作制度》的规定和要求，本着对全体股东负责的 态度，认真履行独立董事职责和义务，谨慎、认真、勤勉地行使公司所赋予的各 项权利，充分发挥独立董事作用。对公司重大事项发表客观、审慎、公正的事前 认可或独立意见，积极维护公司整体利益和全体股东特别是中小股东的合法权益。 现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、独立董事的基本情况 房华先生，1978 年 7 月出生，中国国籍，无境外永久居留权，法学学士。 2000 年 10 月至 2004 年 5 月，任辽宁省律 ...

辽宁春光制药装备股份有限公司 审计报告 大华审字[2024]0011005603 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.gn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 报告编码:京24KG 辽宁春光制药装备股份有限公司 审计报告及财务报表 (2023年1月1日至 2023年12月31日止) | | 录 | 页 次 | | --- | --- | --- | | 审计报告 | | 1-7 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | 4 | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-1 ...

Financial Forecast Revision - The company revised its 2023 net profit forecast to approximately CNY 14,485,200, a decrease of 64.68% compared to the previous year's CNY 41,013,200[4] - The revision was due to increased provisions for expected credit losses on accounts receivable and contract assets, as well as adjustments to prepaid accounts over three years[5] - The performance period for the forecast is from January 1, 2023, to December 31, 2023[3] Risk Warning and Disclosure - The company has issued a risk warning regarding the financial data, advising investors to refer to the detailed annual report for accurate figures[8] - The board of directors has apologized for any inconvenience caused by the forecast revision and committed to improving information disclosure quality in the future[7]

Corporate Recognition and Achievements - In 2023, the company was awarded the title of "Integrity Enterprise" by Jinzhou Credit Association and Jinzhou Small and Medium Enterprises Federation[4] - The company participated in the 25th Annual Golden Bull Award Ceremony in November 2023, winning the "Golden Bull Small Giant Award"[4] - The company was recognized as one of the first "Explosive Products" enterprises in Jinzhou in May 2023[6] Subsidiaries and Business Structure - The company established a wholly-owned subsidiary, Liaoning Jinwang Equipment Installation Engineering Service Co., Ltd., in September 2023[4] - The company included three subsidiaries in the consolidated financial statements, with two newly established subsidiaries in 2023, holding 100% and 60% stakes respectively[114] Financial Performance - The company's operating revenue for 2023 was ¥165,071,927.79, a decrease of 23.61% compared to ¥216,082,516.98 in 2022[27] - The net profit attributable to shareholders for 2023 was ¥14,485,196.39, down 64.68% from ¥41,013,230.25 in 2022[27] - The gross profit margin for 2023 was 32.25%, significantly lower than 47.13% in 2022[27] - Total assets increased by 5.55% to ¥458,091,452.82 at the end of 2023, compared to ¥433,992,572.72 at the end of 2022[29] - Total liabilities rose by 15.08% to ¥174,968,345.64 at the end of 2023, up from ¥152,040,697.45 at the end of 2022[29] - The company's cash flow from operating activities decreased by 83.27% to ¥8,083,726.75 in 2023, compared to ¥48,321,113.32 in 2022[29] - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 5.13% in 2023, down from 34.87% in 2022[27] - The basic earnings per share for 2023 was ¥0.21, a decline of 72.93% from ¥0.78 in 2022[27] Research and Development - The company holds a total of 41 authorized patents, including 12 invention patents, reflecting strong technological innovation capabilities[38] - The company has established a research and innovation mechanism focusing on customer and market needs, enhancing its R&D capabilities through partnerships with universities and research institutions[38] - The company is actively pursuing new technologies and product development, although specific new products were not detailed in the report[88] - R&D expenditure for the current period amounted to ¥9,209,998.60, representing an increase of 3.37% compared to the previous period's ¥8,909,482.96[94] - The increase in R&D costs was driven by a 76.71% rise in material costs due to a shift from collaborative to independent R&D projects[95] Market and Industry Trends - The packaging equipment industry is experiencing growth driven by digital transformation and smart manufacturing, increasing demand for intelligent equipment and production lines[49] - The global packaging industry market size grew from $843.8 billion in 2015 to $914.7 billion in 2019, then decreased to $859.9 billion in 2020 due to economic downturn, with an expected growth to $1.13 trillion by 2030[50] - The global packaging equipment market was valued at $43.6 billion in 2020 and is projected to reach $54.9 billion by 2027, with a CAGR of 3.3%[50] Client Relationships and Sales - Major clients accounted for 39.96% of total sales, with the largest client, Yili, contributing CNY 27,316,911.57, representing 16.55% of total sales[76] - The company has established stable partnerships with leading firms in the pharmaceutical and food sectors, enhancing its market reputation and brand influence[54] Financial Management and Investments - The company has secured loans from various banks, including a 160,000,000.00 CNY loan from Dian Guan Ke Construction Bank, with a repayment period extending to 2031[151] - The company has ongoing investments in the intelligent automation equipment production base, with total actual investment reaching CNY 121,208,930.37 by the end of the reporting period[83] - The company reported a total of 428,400.00 yuan in litigation as a defendant, representing 0.15% of the total net assets at the end of the reporting period[132] Governance and Compliance - The company has established new corporate governance systems during the year, enhancing its internal control mechanisms[194] - The governance mechanism effectively protects the rights of all shareholders, ensuring equal rights and participation in decision-making processes[197] - Major decisions such as external guarantees, investments, and related transactions were conducted in accordance with internal control procedures and legal regulations[200] Employee Management and Development - The company has implemented a competitive salary policy and provides various employee benefits, including health check-ups and commercial insurance[188] - The number of management personnel increased from 23 to 39, with a net addition of 16 personnel during the reporting period[186] - The company has a stable core technical team, with R&D capabilities that are improving, ensuring that their packaging equipment meets or exceeds the functionality of similar imported equipment[125]